Phase II Trial Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk (MDS) Myelodysplastic Syndrome Resistant or Relapsing After ESA Agents (LODEFI)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Deferasirox (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms LODEFI
- 08 Jan 2018 Planned primary completion date changed from 2 Dec 2017 to 1 Jan 2020.
- 08 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Jan 2018.
- 05 Jan 2018 Location has been assumed.